Fig. 6

Clinically applicable panels and biomarkers for the subtyping. a Confusion matrixes and tables of true positive rate, false positive rate, true negative rate and false negative rate of the 16-gene SVM model. b Receiver operating characteristic curve evaluated the predictive potent of the ratio of PRLR and TNFSF13B and the sensitivity and specificity with the cutoff ratio set to 0.85. c Single-cell RNA sequencing (GSE182270) presented the location of PRLR and TNFSF13B. d Immunofluorescence confirmed the location of PRLR (Green: PRLR). e Immunofluorescence confirmed the location of TNFSF13B (Green: TNFSF13B, red: CD11b). f Immunofluorescence co-staining of PRLR and TNFSF13B in representative WIA (upper panel) and IHL subtype patients (lower panel). g Heatmap of immunofluorescence positivity signal rates of PRLR and TNFSF13B for patients (PT) and normal controls (CT). h Predictive ability of the ratio between immunofluorence signals of PRLR and TNFSF13B for determining IHL subtypes/normal and IIA/WIA subtypes